BRIACELL THERAPEUTICS CORP. Stock-Based Compensation
BRIACELL THERAPEUTICS CORP. (BCTX) reported Stock-Based Compensation of $1.01 million for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. share-based payment arrangement, noncash expense for the quarter ending 2026-04-30 was $432.21K, a 92.25% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. share-based payment arrangement, noncash expense for the quarter ending 2026-01-31 was $285.86K, a 0.27% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. share-based payment arrangement, noncash expense for the quarter ending 2025-10-31 was $294.69K, a 10.38% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. share-based payment arrangement, noncash expense for the quarter ending 2025-07-31 was $0.00, a 100.00% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. share-based payment arrangement, noncash expense for fiscal 2025 was $776.88K, a 56.94% decline from fiscal 2024.
- BRIACELL THERAPEUTICS CORP. share-based payment arrangement, noncash expense for fiscal 2024 was $1.80M, a 17.76% decline from fiscal 2023.
- BRIACELL THERAPEUTICS CORP. share-based payment arrangement, noncash expense for fiscal 2023 was $2.19M, a 28.65% decline from fiscal 2022.
- BRIACELL THERAPEUTICS CORP. share-based payment arrangement, noncash expense for fiscal 2022 was $3.07M, a 56.21% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-04-30 | $432.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09 | $718.06K derived: sum of 2 quarters · filed 2026-06-09 | $1.01M 10-Q · filed 2026-06-09 | $1.01M derived: sum of 4 quarters · filed 2026-06-09 |
| 2026-01-31 | $285.86K 10-Q · filed 2026-03-10 | $580.54K 10-Q · filed 2026-03-10 | $580.54K derived: sum of 3 quarters · filed 2026-03-10 | $805.36K derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-10-31 | $294.69K 10-Q · filed 2025-12-11 | $294.69K derived: sum of 2 quarters · filed 2025-12-11 | $519.50K derived: sum of 3 quarters · filed 2025-12-11 | $804.59K derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-07-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $224.81K derived: sum of 2 quarters · filed 2025-10-16 | $509.91K derived: sum of 3 quarters · filed 2026-03-10 | $776.88K 10-K · filed 2025-10-16 |
| 2025-04-30 | $224.81K 10-Q · filed 2025-06-16 | $509.91K derived: sum of 2 quarters · filed 2026-03-10 | $776.88K 10-Q · filed 2026-06-09 | $1.15M derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-01-31 | $285.09K 10-Q · filed 2026-03-10 | $552.06K 10-Q · filed 2026-03-10 | $929.96K derived: sum of 3 quarters · filed 2026-03-10 | $1.32M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-10-31 | $266.97K 10-Q · filed 2025-12-11 | $644.86K derived: sum of 2 quarters · filed 2025-12-11 | $1.04M derived: sum of 3 quarters · filed 2025-12-11 | $1.54M derived: sum of 4 quarters · filed 2025-12-11 |
| 2024-07-31 | $377.89K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $770.11K derived: sum of 2 quarters · filed 2025-10-16 | $1.27M derived: sum of 3 quarters · filed 2025-10-16 | $1.80M 10-K · filed 2025-10-16 |
| 2024-04-30 | $392.21K 10-Q · filed 2025-06-16 | $892.37K derived: sum of 2 quarters · filed 2025-06-16 | $1.43M 10-Q · filed 2025-06-16 | $1.96M derived: sum of 4 quarters · filed 2025-06-16 |
| 2024-01-31 | $500.15K 10-Q · filed 2025-03-12 | $1.03M 10-Q · filed 2025-03-12 | $1.57M derived: sum of 3 quarters · filed 2025-03-12 | $1.85M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-10-31 | $533.82K 10-Q · filed 2024-12-16 | $1.07M derived: sum of 2 quarters · filed 2024-12-16 | $1.35M derived: sum of 3 quarters · filed 2024-12-16 | $1.62M derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | $533.82K derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-29 | $815.00K derived: sum of 2 quarters · filed 2024-10-29 | $1.08M derived: sum of 3 quarters · filed 2024-10-29 | $2.19M 10-K · filed 2024-10-29 |
| 2023-04-30 | $281.19K 10-Q · filed 2023-06-14 | $548.03K derived: sum of 2 quarters · filed 2023-06-14 | $1.66M 10-Q · filed 2024-06-14 | $2.54M derived: sum of 4 quarters · filed 2023-12-14 |
| 2023-01-31 | $266.84K 10-Q · filed 2023-03-16 | $1.38M 10-Q · filed 2024-03-18 | $2.26M derived: sum of 3 quarters · filed 2023-12-14 | $3.12M derived: sum of 4 quarters · filed 2023-12-14 |
| 2022-10-31 | $1.11M 10-Q · filed 2023-12-14 | $1.99M derived: sum of 2 quarters · filed 2023-12-14 | $2.85M derived: sum of 3 quarters · filed 2023-12-14 | $3.67M derived: sum of 4 quarters · filed 2023-12-14 |
| 2022-07-31 | $877.95K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-25 | $1.74M derived: sum of 2 quarters · filed 2023-10-25 | $2.56M derived: sum of 3 quarters · filed 2023-10-25 | $3.07M 10-K · filed 2023-10-25 |
| 2022-04-30 | $863.63K 10-Q · filed 2023-06-14 | $1.68M derived: sum of 2 quarters · filed 2023-06-14 | $2.20M 10-Q · filed 2023-06-14 | |
| 2022-01-31 | $814.88K 10-Q · filed 2023-03-16 | $1.33M 10-Q · filed 2023-03-16 | ||
| 2021-10-31 | $518.13K 10-Q · filed 2022-12-14 | |||
| 2021-07-31 | $1.97M 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |